Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Feinstein Institutes Researcher Discovers Potential Therapeutic Target for Lethal Sepsis
Details : The research explores the identification of mAbs working against a pro-inflammatory protein mediator, pCTS-L. These anti-pCTS-L monoclonal antibodies may provide effective therapies for the clinical treatment of human sepsis and other infectious diseases...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famotidine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Famotidine Cinical Trial Shows Reduction in Covid-19 Symptoms
Details : Famotidine is a safe, low-cost, over-the-counter drug usually used to treat heartburn. People with Covid-19 often get sick because the body’s inflammatory response to the virus gets overactivated.
Product Name : Pepcid
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2022
Lead Product(s) : Famotidine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famotidine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows
Details : The preclinical study published that Pepcid (famotidine), a histamine 2 receptor (H2R) antagonist, prevents cytokine storm in mice, famotidine did this indirectly because it stimulated signals caused by vagus nerve, a major nerve into the body’s organs...
Product Name : Pepcid
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Famotidine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The findings published in the JAMA Psychiatry showed that after two weeks of daily treatment, women treated with zuranolone had a statistically significant reduction in their core symptoms of depression compared to women who received a placebo.
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone,Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Feinstein Institutes Researchers Find Effective COVID-19 ‘Cytokine Storm’ Treatment
Details : Results from the study showed that the most effective treatment was the combination of corticosteroids-such as dexamethasone – with tocilizumab when compared to standard of care.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Dexamethasone,Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Feinstein Institutes to Collect COVID-19 Patient Plasma, Research Antibodies Therapy
Details : Northwell Health joins the convalescent plasma network formed by Mayo Clinic to investigate COVID-19 antibody tests and inoculation treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials
Details : The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2020
Lead Product(s) : Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable